Orgenesis Inc. (ORGS) and GlycoMimetics Inc. (NASDAQ:GLYC) Comparison side by side

We will be contrasting the differences between Orgenesis Inc. (NASDAQ:ORGS) and GlycoMimetics Inc. (NASDAQ:GLYC) as far as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orgenesis Inc. 18.66M 4.19 19.18M -1.40 0.00
GlycoMimetics Inc. N/A 0.00 48.27M -1.13 0.00

Table 1 shows the gross revenue, earnings per share and valuation for Orgenesis Inc. and GlycoMimetics Inc.

Profitability

Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Orgenesis Inc. -102.79% -70.9% -31.2%
GlycoMimetics Inc. 0.00% -21.7% -20.9%

Risk & Volatility

A beta of 1.37 shows that Orgenesis Inc. is 37.00% more volatile than Standard & Poor’s 500. From a competition point of view, GlycoMimetics Inc. has a 2.73 beta which is 173.00% more volatile compared to Standard & Poor’s 500.

Liquidity

The Current Ratio and a Quick Ratio of Orgenesis Inc. are 1.8 and 1.7. Competitively, GlycoMimetics Inc. has 34.6 and 34.6 for Current and Quick Ratio. GlycoMimetics Inc.’s better ability to pay short and long-term obligations than Orgenesis Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for Orgenesis Inc. and GlycoMimetics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Orgenesis Inc. 0 0 0 0.00
GlycoMimetics Inc. 0 0 1 3.00

Competitively GlycoMimetics Inc. has a consensus target price of $23, with potential upside of 101.40%.

Institutional and Insider Ownership

Orgenesis Inc. and GlycoMimetics Inc. has shares held by institutional investors as follows: 2.8% and 0%. About 26.45% of Orgenesis Inc.’s share are held by insiders. Comparatively, 0.2% are GlycoMimetics Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Orgenesis Inc. -0.77% 19.44% -9.63% -18.23% -35.5% 10.26%
GlycoMimetics Inc. -2.13% 6.43% -1.65% -20.74% -49.3% 25.87%

For the past year Orgenesis Inc.’s stock price has smaller growth than GlycoMimetics Inc.

Summary

On 7 of the 10 factors GlycoMimetics Inc. beats Orgenesis Inc.

Orgenesis Inc., a biopharmaceutical company, develops trans-differentiation technologies in the field of cell therapy and regenerative medicine. The company's Contract Development and Manufacturing Organization segment specializes in cell therapy development for advanced medicinal products. This segment provides process and assay development services; and GMP contract manufacturing services. Its Cellular Therapy Business segment develops cell trans-differentiation technology induce shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell-like insulin-producing cells for patients with diabetes. Orgenesis Inc. has a collaboration agreement with Biosequel LLC to carry out clinical trials and market its products in Russia, Belarus, and Kazakhstan. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.